Use patterns and self-reported effects of Salvia divinorum: An internet-based survey

Drug and Alcohol Dependence

Volumn 111, Issue 3, 2010, Pages 250-256

  Baggott, M J ^a,b   Erowid, Earth ^c   Erowid, Fire ^c   Galloway, Gantt P ^b   Mendelson, John ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b California Pacific Research Institute   (United States)

^c Erowid Center   (United States)

Author keywords

Hallucinogen; Kappa opioid; Patterns of use; Salvia divinorum; Subjective effects

Indexed keywords

ADULT; ANXIETY; ARTICLE; CONSCIOUSNESS DISORDER; FEMALE; HALLUCINATION; HUMAN; INTERNET; MALE; PRIORITY JOURNAL; SALVIA; SALVIA DIVINORUM; SELF REPORT; SMOKING; SOCIAL BEHAVIOR; SUBSTANCE ABUSE;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AFFECT; AGED; DATA COLLECTION; FEMALE; HALLUCINOGENS; HUMANS; INTERNET; MALE; MIDDLE AGED; PLANT EXTRACTS; PROSPECTIVE STUDIES; RECEPTORS, OPIOID, KAPPA; SALVIA; SELF REPORT; YOUNG ADULT;

SALVIA DIVINORUM;

EID: 77957310716     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2010.05.003     Document Type: Article

References (67)

1. Aardvark D. Salvia divinorum and Salvinorin A 1998, ER Monograph Series. 2nd ed.
2. Abel K.M., O'Keane V., Murray R.M. Enhancement of the prolactin response to d-fenfluramine in drug-naive schizophrenic patients. Br. J. Psychiatry 1996, 168:57-60.
3. Aldrich J.V., Vigil-Cruz S.C. Narcotic analgesics. Burger's Medicinal Chemistry & Drug Discovery 2003, John Wiley & Sons, New York, NY. D.J.E. Abraham (Ed.).
4. Ashton N., Balment R.J., Blackburn T.P. Kappa-opioid-induced changes in renal water and electrolyte management and endocrine secretion. Br. J. Pharmacol. 1989, 97:769-776.
5. Barrett A.C., Smith E.S., Picker M.J. Sex-related differences in mechanical nociception and antinociception produced by mu- and kappa-opioid receptor agonists in rats. Eur. J. Pharmacol. 2002, 452:163-173.
6. Beadles-Bohling A.S., Wiren K.M. Anticonvulsive effects of kappa-opioid receptor modulation in an animal model of ethanol withdrawal. Genes Brain Behav. 2006, 5:483-496.
7. Butelman E.R., Harris T.J., Kreek M.J. The plant-derived hallucinogen, salvinorin A, produces kappa-opioid agonist-like discriminative effects in rhesus monkeys. Psychopharmacology 2004, 172:220-224.
8. Butelman E.R., Prisinzano T.E., Deng H., Rus S., Kreek M.J. Unconditioned behavioral effects of the powerful {kappa}-opioid hallucinogen, salvinorin A: fast onset and entry into cerebrospinal fluid. J. Pharmacol. Exp. Ther. 2008.
9. Carlezon W.A., Beguin C., DiNieri J.A., Baumann M.H., Richards M.R., Todtenkopf M.S., Rothman R.B., Ma Z., Lee D.Y., Cohen B.M. Depressive-like effects of the kappa-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats. J. Pharmacol. Exp. Ther. 2006, 316:440-447.
10. Carroll F.I., Harris L.S., Aceto M.D. Effects of JDTic, a selective kappa-opioid receptor antagonist, on the development and expression of physical dependence on morphine using a rat continuous-infusion model. Eur. J. Pharmacol. 2005, 524:89-94.
11. Chappell P.B., Leckman J.F., Scahill L.D., Hardin M.T., Anderson G., Cohen D.J. Neuroendocrine and behavioral effects of the selective kappa agonist spiradoline in Tourette's syndrome: a pilot study. Psychiatry Res. 1993, 47:267-280.
12. Chavkin C., Sud S., Jin W., Stewart J., Zjawiony J.K., Siebert D.J., Toth B.A., Hufeisen S.J., Roth B.L. Salvinorin A, an active component of the hallucinogenic sage Salvia divinorum is a highly efficacious kappa-opioid receptor agonist: structural and functional considerations. J. Pharmacol. Exp. Ther. 2004, 308:1197-1203.
13. Chefer V.I., Czyzyk T., Bolan E.A., Moron J., Pintar J.E., Shippenberg T.S. Endogenous kappa-opioid receptor systems regulate mesoaccumbal dopamine dynamics and vulnerability to cocaine. J. Neurosci. 2005, 25:5029-5037.
14. Craft R.M., Bernal S.A. Sex differences in opioid antinociception: kappa and 'mixed action' agonists. Drug Alcohol Depend. 2001, 63:215-228.
15. Dennehy C.E., Tsourounis C., Miller A.E. Evaluation of herbal dietary supplements marketed on the internet for recreational use. Ann. Pharmacother. 2005, 39:1634-1639.
16. Epling C., Jativa M. A new species of salvia from Mexico 1962, vol. 20. Botanical Museum Leaflets Harvard University, pp. 75-76.
17. Erowid, 2008. Erowid Salvia divinorum (Ska Pastora) Vault. (Accessed on 22.12.08). http://www.erowid.org/plants/salvia.
18. Eysenbach G., Wyatt J. Using the Internet for surveys and health research. J. Med. Internet Res. 2002, 4:E13.
19. Gaveriaux-Ruff C., Kieffer B.L. Opioid receptor genes inactivated in mice: the highlights. Neuropeptides 2002, 36:62-71.
20. Gear R.W., Gordon N.C., Heller P.H., Paul S., Miaskowski C., Levine J.D. Gender difference in analgesic response to the kappa-opioid pentazocine. Neurosci. Lett. 1996, 205:207-209.
21. Gonzalez D., Riba J., Bouso J.C., Gomez-Jarabo G., Barbanoj M.J. Pattern of use and subjective effects of Salvia divinorum among recreational users. Drug Alcohol Depend. 2006, 85:157-162.
22. Gruber J.W. High performance liquid chromatographic quantification of salvinorin A from tissues of Salvia divinorum Epling & Játiva-M. Phytochem. Anal. 1999, 10:22-25.
23. Hanes K.R. Antidepressant effects of the herb Salvia divinorum: a case report. J. Clin. Psychopharmacol. 2001, 21:634-635.
24. Hooker J.M., Xu Y., Schiffer W., Shea C., Carter P., Fowler J.S. Pharmacokinetics of the potent hallucinogen, salvinorin A in primates parallels the rapid onset and short duration of effects in humans. NeuroImage 2008, 41:1044-1050.
25. Johnson J. The elements of Mazatec witchcraft. Göteborgs Etnografiska Museum Etnologiska Stud. 1939, 9:119-149.
26. Khey D.N., Miller B.L., Griffin O.H. Salvia divinorum use among a college student sample. Baywood 2008, 297-306.
27. Kieffer B.L., Gaveriaux-Ruff C. Exploring the opioid system by gene knockout. Prog. Neurobiol. 2002, 66:285-306.
28. Kovacs K.M., Szakall I., O'Brien D., Wang R., Vinod K.Y., Saito M., Simonin F., Kieffer B.L., Vadasz C. Decreased oral self-administration of alcohol in kappa-opioid receptor knock-out mice. Alcohol Clin. Exp. Res. 2005, 29:730-738.
29. Kramer H.J., Uhl W., Ladstetter B., Backer A. Influence of asimadoline, a new kappa-opioid receptor agonist, on tubular water absorption and vasopressin secretion in man. Br. J. Clin. Pharmacol. 2000, 50:227-235.
30. Lange J.E., Daniel J., Homer K., Reed M.B., Clapp J.D. Salvia divinorum: effects and use among YouTube users. Drug Alcohol Depend. 2009, 108(1):138-140.
31. Lange J.E., Reed M.B., Croff J.M., Clapp J.D. College student use of Salvia divinorum. Drug Alcohol Depend. 2008, 94:263-266.
32. Linton H.B., Langs R.J., Paul I.H. Retrospective alterations on the Lsd-25 experience. J. Nervous Mental Dis. 1964, 138:409-423.
33. Mague S.D., Pliakas A.M., Todtenkopf M.S., Tomasiewicz H.C., Zhang Y., Stevens W.C., Jones R.M., Portoghese P.S., Carlezon W.A. Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats. J. Pharmacol. Exp. Ther. 2003, 305:323-330.
34. Martin W.R., Fraser H.F., Gorodetzky C.W., Rosenberg D.E. Studies of the dependence-producing potential of the narcotic antagonist 2-cyclopropylmethyl-2'-hydroxy-5,9-dimethyl-6,7-benzomorphan (cyclazocine, WIN-20,740, ARC II-c-3). J. Pharmacol. Exp. Ther. 1965, 150:426-436.
35. McLaughlin J.P., Land B.B., Li S., Pintar J.E., Chavkin C. Prior activation of kappa opioid receptors by U50,488 mimics repeated forced swim stress to potentiate cocaine place preference conditioning. Neuropsychopharmacology 2006, 31:787-794.
36. Mitchell J.M., Liang M.T., Fields H.L. A single injection of the kappa opioid antagonist norbinaltorphimine increases ethanol consumption in rats. Psychopharmacology 2005, 182:384-392.
37. Mogil J.S., Wilson S.G., Chesler E.J., Rankin A.L., Nemmani K.V., Lariviere W.R., Groce M.K., Wallace M.R., Kaplan L., Staud R., Ness T.J., Glover T.L., Stankova M., Mayorov A., Hruby V.J., Grisel J.E., Fillingim R.B. The melanocortin-1 receptor gene mediates female-specific mechanisms of analgesia in mice and humans. Proc. Natl. Acad. Sci. USA 2003, 100:4867-4872.
38. Negus, S.S., Mello, N.K., 1996. Effect of the kappa opioid agonist EKC on cocaine and food self-administration in rhesus monkeys. Abstracts of CPDD 1996 Annual Meeting, 99.
39. Negus S.S., Zuzga D.S., Mello N.K. Sex differences in opioid antinociception in rhesus monkeys: antagonism of fentanyl and U50,488 by quadazocine. J. Pain. 2002, 3:218-226.
40. Newton S.S., Thome J., Wallace T.L., Shirayama Y., Schlesinger L., Sakai N., Chen J., Neve R., Nestler E.J., Duman R.S. Inhibition of cAMP response element-binding protein or dynorphin in the nucleus accumbens produces an antidepressant-like effect. J. Neurosci. 2002, 22:10883-10890.
41. Ortega A., Blount J.F., Manchand P.D. Salvinorin, a new trans-neoclerodane diterpene from Salvia divinorum (Labiatae). J. Chem. Soc., Perkins Trans. I 1982, 2505-2508.
42. Ott J. Pharmacotheon: Entheogenic Drugs, Their Plant Sources and History 1993, Natural Products Co., Kennewick, WA.
43. Paulzen M., Grunder G. Toxic psychosis after intake of the hallucinogen salvinorin A. J. Clin. Psychiatry 2008, 69:1501.
44. Pavarin R.M. Substance use and related problems: a study on the abuse of recreational and not recreational drugs in Northern Italy. Annali dell'Istituto Superiore di Sanita 2006, 42:477-484.
45. Pendell D. Pharmaco/Poeia: Plant Powers, Poisons, Herbcraft 1995, Mercury House, San Francisco, CA.
46. Pfeiffer A., Brantl V., Herz A., Emrich H.M. Psychotomimesis mediated by kappa opiate receptors. Science 1986, 233:774-776. New York, NY.
47. Pliakas A.M., Carlson R.R., Neve R.L., Konradi C., Nestler E.J., Carlezon W.A. Altered responsiveness to cocaine and increased immobility in the forced swim test associated with elevated cAMP response element-binding protein expression in nucleus accumbens. J. Neurosci. 2001, 21:7397-7403.
48. R Development Core Team R: A Language and Environment for Statistical Computing 2007, R Foundation for Statistical Computing, Vienna, Austria.
49. Reece P.A., Sedman A.J., Rose S., Wright D.S., Dawkins R., Rajagopalan R. Diuretic effects, pharmacokinetics, and safety of a new centrally acting kappa-opioid agonist (CI-977) in humans. J. Clin. Pharmacol. 1994, 34:1126-1132.
50. Rimoy G.H., Wright D.M., Bhaskar N.K., Rubin P.C. The cardiovascular and central nervous system effects in the human of U-62066E. A selective opioid receptor agonist. Eur. J. Clin. Pharmacol. 1994, 46:203-207.
51. Roth B.L., Baner K., Westkaemper R., Siebert D., Rice K.C., Steinberg S., Ernsberger P., Rothman R.B. Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proc. Natl. Acad. Sci. USA 2002, 99:11934-11939.
52. Salvia Authors, 2009. The community Salvia divinorum Frequently Asked Questions file. (Accessed on 13.10.09). http://www.erowid.org/plants/salvia/salvia_faq.shtml.
53. Schmidt M.D., Schmidt M.S., Butelman E.R., Harding W.W., Tidgewell K., Murry D.J., Kreek M.J., Prisinzano T.E. Pharmacokinetics of the plant-derived kappa-opioid hallucinogen salvinorin A in nonhuman primates. Synapse 2005, 58:208-210. New York, NY.
54. Siebert D. Salvinorin A: notes of caution. Entheogen Rev. 1994, 3.
55. Siebert D.J. Salvia divinorum and salvinorin A: new pharmacologic findings. J. Ethnopharmacol. 1994, 43:53-56.
56. Siebert, D.J., 2009. The Salvia divinorum Frequently Asked Questions file. (Accessed on 19.10.09). http://www.sagewisdom.org/faq.html.
57. Singh S. Adolescent salvia substance abuse. Addiction 2007, 102:823-824.
58. Sociedad para la Preservacion de las Plantas del Misterio, 1998. Salvia divinorum Grower's Guide.
59. Spanagel R., Herz A., Shippenberg T.S. The effects of opioid peptides on dopamine release in the nucleus accumbens: an in vivo microdialysis study. J. Neurochem. 1990, 55:1734-1740.
60. Substance Abuse and Mental Health Services Administration, 2008. The NSDUH Report: Use of Specific Hallucinogens: 2006. Rockville, MD.
61. Tsujikawa K., Kuwayama K., Miyaguchi H., Kanamori T., Iwata Y.T., Yoshida T., Inoue H. Determination of salvinorin A and salvinorin B in Salvia divinorum-related products circulated in Japan. Forensic Sci. Int. 2008, 180:105-109.
62. Turner D. Salvinorin-The Psychedelic Essence of Salvia divinorum 1996, Panther Press.
63. Valdés L.J., Butler W.M., Hatfield G.M., Paul A.G., Koreeda M. Divinorin A, a psychotropic terpenoid, and divinorin B, from the hallucinogenic Mexican mint, Salvia divinorum. J. Organic Chem. 1984, 49:4716-4720.
64. Vohra R., Seefeld A., Cantrell F.L., Clark R.F. Salvia divinorum: exposures reported to a statewide poison control system over 10 years. J. Emerg. Med. 2009, Online Preprint.
65. Walsh S.L., Strain E.C., Abreu M.E., Bigelow G.E. Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans. Psychopharmacology 2001, 157:151-162.
66. Xuei X., Dick D., Flury-Wetherill L., Tian H.J., Agrawal A., Bierut L., Goate A., Bucholz K., Schuckit M., Nurnberger J., Tischfield J., Kuperman S., Porjesz B., Begleiter H., Foroud T., Edenberg H.J. Association of the kappa-opioid system with alcohol dependence. Mol. Psychiatry 2006, 11:1016-1024.
67. Zapata A., Shippenberg T.S. Endogenous kappa opioid receptor systems modulate the responsiveness of mesoaccumbal dopamine neurons to ethanol. Alcohol Clin. Exp. Res. 2006, 30:592-597.